TET3 and ovarian cancer: When treatment of acquired platinum-resistant ovarian cancer with guadecitabine (DNMT inhibitor) and carboplatin, TET3 expression is dramatically up-regulated (logFC = 1.04, GSE102118 [40], data not shown), indicating that TET3 can have a role with the combination of DNMT or other methylases.